Transfusion and Apheresis Science
Volume 42, Issue 3 , Pages 239-245, June 2010

Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation

Gazi University, Faculty of Medicine, Department of Hematology, Ankara, Turkey

Received 16 May 2009

Abstract 

Leukemia relapse is a serious therapeutic challenge following hematopoietic stem cell transplantation (HSCT). In this retrospective study, 23 patients [15 (65.2%) AML, 8 (34.8%) ALL] who received DLI±reinduction chemotherapy for post-transplant relapse were reviewed. The overall response rate of DLI was 66.7% for AML and 50% for ALL. A total of 15 patients (65.2%) developed acute graft versus host disease (GVHD). Response rates were higher in patients with GVHD (80% versus 25%; p=0.01; OR: 12.0). The probability of OS was better in patients who respond to DLI (p=0.04). Further strategies are required to improve the anti-tumor properties of alloreactive donor lymphocytes and to obtain durable responses with DLI in patients with relapsed acute leukemia after allogeneic HSCT.

Keywords: Acute leukemia, Donor lymphocyte infusion, Hematopoietic stem cell transplantation

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1473-0502(10)00063-7

doi:10.1016/j.transci.2010.03.011

Transfusion and Apheresis Science
Volume 42, Issue 3 , Pages 239-245, June 2010

Article Tools

* Image Usage & Resolution